Zhongnan Medical Journal Press

Home Results

A total of 5 result was found. Results that relate to Progression-free survival

Real-world study of sintilimab combined with bevacizumab in patients with advanced hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(3):485-490.
13922 times 2795 times

SU Zhan CHE Jinhui PEI Ruifeng

Advanced hepatocellular carcinoma Sintilimab Bevacizumab Clinical efficacy Safety Overall survival Progression-free survival
Details
Efficacy and safety of tislelizumab combined with sorafenib in the treatment for unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(8):1136-1342.
10661 times 2394 times

JIANG Jinghua HU Yiting

Tirilizumab Sorafenib Unresectable Hepatocellular carcinoma Objective response rate Disease control rate Progression-free survival Overall survival
Details
Effects of statins on survival outcomes in patients with metastatic renal cell carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,28(1):28-33.
10739 times 1674 times

GAO Shiliang HE Xiaoqi ZHENG Huijie YANG Di YU Mingzhu

Metastatic renal cell carcinoma Statins Survival outcomes Overall survival Progression-free survival Objective response rate Disease control rate
Details
The impact of postoperative transcatheter arterial infusion and systemic adjuvant therapy on prognosis in patients with R1 resection for hilar cholangiocarcinoma

Published on New Medicine 2026,36(4):385-392.
3053 times 1305 times

GENG Qin QIAN Chunxing LI Guowang KANG Qiang KE Yang LI Jing YANG Chen LI Yuehua

Hilar cholangiocarcinoma R1 resection Postoperative adjuvant therapy Transcatheter arterial infusion Overall survival Progression-free survival
Details
Efficacy evaluation and quality of life analysis of cadonilimab combined with bevacizumab biosimilar and chemotherapy in the treatment of metastatic colorectal cancer

Published on Frontiers in Pharmaceutical Sciences 2026,30(9):1538-1548.
654 times 169 times

ZHANG Xiaoqing LIU Shuai ZHANG Kai HE Jing WANG Yuchao ZHANG Juan LUAN Wei

Cadonilimab Bevacizumab Metastatic colorectal cancer Efficacy evaluation RAS-mutated Progression-free survival Objective response rate Disease control rate
Details